Blood Contamination of Root Canal During Endodontic TherapyNCT03336853
A New Approach for Controlling Hemostasis During Canal Treatment
A study testing HybenX in people with Blood Contamination of Root Canal During Endodontic Therapy, run by Dr Riccardo Pace at 1 site in Italy.
Trial summary
The persistence of blood may significantly affect final sealing with the persistence of microleakage (Zmener et al. 2008, Roggendorf et al. 2007). In cases of copious bleeding from root canals, calcium hydroxide, anesthetic solution with 1:50,000 epinephrine or ferric sulfate placed on a sterile paper cone, are… Read more about this study
- Who is it for?
- Ages 20 to 60 years
- Conditions the study is for
- Blood Contamination of Root Canal During Endodontic Therapy
- What is being tested?
- HybenX
- Type of treatment
- Injection or infusion, Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteItaly
- Study dates
- 1 Apr 2017to 22 Dec 2017
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- patients aged between 20 and 60 years
- patients able and willing to sign a consent form,
- single-rooted teeth with necrotic pulp confirmed by electric vitality test
- healthy periodontium
- physiologic sulcus depth (<3 mm)
- absence of bleeding on probing of the involved teeth.
Who cannot join
- patients with systemic diseases
- patients using anticoagulants in the last 30 days
- patients using antibiotics in the last 30 days
- patients using anti-inflammatory therapies in the last 30 days
- patients with allergy to sulfur in any form
- pregnancy.
- All subjects were informed of the nature and potential risks and benefits of their participation in the study
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A New Approach for Controlling Hemostasis During Canal Treatment: a Randomized Controlled Study
The persistence of blood may significantly affect final sealing with the persistence of microleakage (Zmener et al. 2008, Roggendorf et al. 2007).
In cases of copious bleeding from root canals, calcium hydroxide, anesthetic solution with 1:50,000 epinephrine or ferric sulfate placed on a sterile paper cone, are recognized as effective hemostatic agents (Magnusson 1971, Kouri et al. 1969, Dannenberg 1974).
The purpose of this study was to test the reduction of root canal bleeding in terms of significant percentage change for millimeters of blood in the canal at 2 different time points (baseline and after treatment with HybenX )
Read the detailed description
A new device (HYBENX®, EPIEN Medical, Saint Paul, MN, USA) has been developed with the purpose of destroying dental biofilm. The material is a mixture of hydroxybenzenesulfonic acid (37%) and hydroxymethoxybenzene acids (23%), sulfuric acid (28%), and water (12%).
This device has been successfully used in periodontology. Recent studies (Pini-Prato et al. 2016a, Isola et al. 2017) have demonstrated the effectiveness of the oral tissue decontaminant material in the treatment of clinical cases showing acute periodontal abscess without the use of systemic or local antibiotics. Similar favorable effects were obtained in the treatment of peri-implant mucositis and peri-implantitis (Pini-Prato et al. 2016b, Lopez et al. 2016). In addition, a randomized controlled trial (RCT) also demonstrated beneficial effects of the material in the treatment of oral aphthae (Porter et al. 2009).
Based on this scientific information, a clinical and microbiological study has been planned using the decontaminant device in cases of teeth with necrotic pulp with the aim to destroy the dental biofilm of root canals. The ability of the decontaminant device to immediately stop bleeding during canal instrumentation was found out accidentally during the procedures of this still unpublished trial.
Due to this fact, the authors were interested in evaluating the coagulation property of the material. The purpose of this study was to test the reduction of root canal bleeding in terms of significant percentage change for millimeters of blood in the canal at 2 different time points (before and after treatment with HybenX ) A single center, participants and data analyst blind, two-arm, randomized, placebo controlled clinical trial study was performed following the CONSORT statement in the Endodontics Department, University Hospital Florence Careggi, Florence, Italy.
The study population consisted of patients that were treated by Endodontics Department of the University Hospital of Florence Careggi, Italy. Subject inclusion criteria were: patients aged between 20 and 60 years, able and willing to sign a consent form, single-rooted teeth with necrotic pulp confirmed by electric vitality test, associated with healthy periodontium, physiologic sulcus depth (<3 mm), and absence of bleeding on probing of the involved teeth.
Exclusion criteria were: patients with systemic diseases using anticoagulants, antibiotics, or anti-inflammatory therapies in the last 30 days, patients with allergy to sulfur in any form, and pregnancy. All subjects were informed of the nature and potential risks and benefits of their participation in the study. They also received information on the duration of the procedure, and the possible intraoperative and postoperative complications.
Treatment The root canal therapy procedure was standardized and limited to one experienced endodontist (R.P.). Treatments were performed at the Endodontics Departments of the University Hospital of Florence Careggi, Italy, under local anesthesia using 1.8 mL mepivacaine hydrochloride (Optocaine; Molteni Dental SRL, Scandicci, Italy), and the teeth were isolated with rubber dams. After preparing the access cavity, the working length was determined with an electronic apex locator (Propex II Dentsply Maillefer Instruments, Ballaigues, Switzerland) with a size 10 k-file. Root canals were shaped using ProTaper Universal NiTi files (Dentsply Maillefer Instruments, Ballaigues, Switzerland) in the following sequence: S1, S2, F1, F2, F3 until each instrument reached the working length. After each instrument, the root canals were rinsed with NaClO (Niclor 5, Ogna, Italy) using a syringe with a side-vented 30 G needle. ProTaper NiTi instruments were driven with an endodontic motor (XSmart Endo Motor, Dentsply Maillefer Instruments, Ballaigues, Switzerland) with a 16:1 contrangle set up as suggested by the manufacturer.
After the root canal, shaping was performed, and a first sterile paper point was introduced in the root canal, up to the working length, for 10 seconds to detect blood presence.
With a caliber, on the sterile paper cone, the millimeters of blood present within the root canal were measured.
Only the teeth that at this point showed 1 or more millimeters of blood within the root canal were included in the present study and randomized to the two experimental groups.
Before further treatment, the teeth were allocated to an experimental (HybenX) or a control group (sterile saline solution) according to an uneven block randomization designed by the statistician (A.N.). For each tooth, a closed envelope was opened in a consecutive order, assigning the tooth to either the experimental or the control group HybenX was approved as a Class I CE medical device by the Italian Ministry of Health (no. 483768) on February 7, 2012.
HybenX Group The material was introduced inside the root canal using the pre-dosed syringe for 20 seconds with a sterile paper point with and up and down movement up to the working length.
Finally, the canal was rinsed with sterile water using a syringe with a side-vented 30 G needle 1 mm shorter than the working length.
A second sterile paper point was introduced in the root canal, up to the working length, for 10 seconds to detect the presence of blood and the millimeters of blood inside the root canal was measured again according the previous criteria.
Statistical Analysis Data were analyzed using SAS Version 9.3 software (SAS Institute, Inc., Cary, NC). A preliminary Levene's test was performed to verify the homogeneity of variance for the percentage change in the two groups.
Since the two groups showed homogeneity of the variance a t-test was performed to verify the null hypothesis by using a type I error equal to 0.05.
In order to confirm the firmness of the results a Wilcoxon non-parametric test was also carried out.
- Being tested
- HybenX, Placebo control
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
HybenXDevice
The material was introduced inside the root canal using the pre-dosed syringe for 20 seconds with a sterile paper point with and up and down movement up to the working length.
Finally, the canal was rinsed with sterile water using a syringe with a side-vented 30 G needle 1 mm shorter than the working length.
A second sterile paper point was introduced in the root canal, up to the working length, for 10 seconds to detect the presence of blood and the millimeters of blood inside the root canal was measured again according the previous criteria.
Placebo controlOther
The root canal was irrigated with sterile saline water with a syringe and a side-vented 30G needle activated for 20 seconds with a sterile paper point with and up and down movement up to the working length to ensure a flow of irrigant solution throughout the canal.
Finally, the canal was rinsed with sterile water using a syringe with a side-vented 30 G needle 1 mm shorter than the working length. A second sterile paper point was introduced in the root canal, up to the working length, for 10 seconds to detect the presence of blood and the millimeters of blood inside the root canal was measured again according the previous criteria.
| Study group | Role | What they receive |
|---|---|---|
| HybenX ® | Experimental | 1 cc of mixture of hydroxybenzenesulfonic acid (37%) and hydroxymethoxybenzene acids (23%), sulfuric acid (28%), and water (12%) for 20 sec Receives: Device: HybenX |
| Control | Placebo comparator | 5 cc of sterile saline water for 20 sec Receives: Other: Placebo control |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline in Root Canal Bleeding
After the root canal, shaping was performed a first sterile paper point was introduced in the root canal, up to the working length, to detect blood presence.
The millimeters of blood on the paper point were measured with a caliber. After the intervention (HybenX or placebo) a second sterile paper point was introduced in the root canal, up to the working length, to detect the presence of blood according the previous criteria
Measured: Baseline and After Treatment (20 seconds)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Nov 2017
- Study start1 Apr 2017
- Primary completion21 Jul 2017
- Study completion22 Dec 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (10)Papers the sponsor has linked to this study.
- Other trials for Blood Contamination of Root Canal During Endodontic TherapyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- single center, participants and data analyst blind, two-arm, randomized, placebo controlled clinical trial study
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Dr Riccardo Pace
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Dr Riccardo Pace, Azienda Ospedaliero-Universitaria Careggi
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03336853
- Sponsor's protocol ID
- endo 2-2017
- Status last verified
- Mar 2019
- First submitted
- 27 Oct 2017
- Last updated
- 26 Mar 2019
- Results posted
- Yes, on ClinicalTrials.gov
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Publications
Pini-Prato G, Magnani C, Rotundo R. Nonsurgical Treatment of Peri-implantitis Using the Biofilm Decontamination Approach: A Case Report Study. Int J Periodontics Restorative Dent. 2016 May-Jun;36(3):383-91. doi: 10.11607/prd.2653.
PubMed 27100808Lopez MA, Andreasi Bassi M, Confalone L, Silvestre F, Arcuri C. The treatment of peri-implant diseases: a new approach using hybenx(R) as a decontaminant for implant surface and oral tissues. Oral Implantol (Rome). 2016 Nov 13;9(3):106-114. doi: 10.11138/orl/2016.9.3.106. eCollection 2016 Jul-Sep.
PubMed 28042438Porter SR, Al-Johani K, Fedele S, Moles DR. Randomised controlled trial of the efficacy of HybenX in the symptomatic treatment of recurrent aphthous stomatitis. Oral Dis. 2009 Mar;15(2):155-61. doi: 10.1111/j.1601-0825.2008.01503.x.
PubMed 19207485Zmener O, Pameijer CH, Serrano SA, Vidueira M, Macchi RL. Significance of moist root canal dentin with the use of methacrylate-based endodontic sealers: an in vitro coronal dye leakage study. J Endod. 2008 Jan;34(1):76-9. doi: 10.1016/j.joen.2007.10.012.
PubMed 18155498Roggendorf MJ, Ebert J, Petschelt A, Frankenberger R. Influence of moisture on the apical seal of root canal fillings with five different types of sealer. J Endod. 2007 Jan;33(1):31-3. doi: 10.1016/j.joen.2006.07.006. Epub 2006 Oct 13.
PubMed 17185125Magnusson B. Therapeutic pulpotomy in primary molars--clinical and histological follow-up. II. Zinc oxide-eugenol as wound dressing. Odontol Revy. 1971;22(1):45-54. No abstract available.
PubMed 5280515Kouri EM, Matthews JL, Taylor PP. Epinephrine in pulpotomy. ASDC J Dent Child. 1969 Mar-Apr;36(2):123-8. No abstract available.
PubMed 4888301Dannenberg JL. Pedodontic endodontics. Dent Clin North Am. 1974 Apr;18(2):367-77. No abstract available.
PubMed 4274315Isola G, Matarese G, Williams RC, Siciliano VI, Alibrandi A, Cordasco G, Ramaglia L. The effects of a desiccant agent in the treatment of chronic periodontitis: a randomized, controlled clinical trial. Clin Oral Investig. 2018 Mar;22(2):791-800. doi: 10.1007/s00784-017-2154-7. Epub 2017 Jun 17.
PubMed 28624914Pini-Prato G, Magnani C, Rotundo R. Treatment of Acute Periodontal Abscesses Using the Biofilm Decontamination Approach: A Case Report Study. Int J Periodontics Restorative Dent. 2016 Jan-Feb;36(1):55-63. doi: 10.11607/prd.2557.
PubMed 26697553
Study at a glance
From the registry record, last updated by the sponsor on 26 Mar 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A New Approach for Controlling Hemostasis During Canal Treatment: a Randomized Controlled Study
- ClinicalTrials.gov ID
- NCT03336853
- Acronym / sponsor ID
- endo 2-2017
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Dr Riccardo PaceUniversity, hospital or other
- Study start
- 1 Apr 2017 (actual)
- Primary completion
- 21 Jul 2017 (actual)
- Study completion
- 22 Dec 2017 (actual)
- First posted
- 8 Nov 2017 (actual)
- Results
- Posted 13 Mar 2019
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The persistence of blood may significantly affect final sealing with the persistence of microleakage (Zmener et al. 2008, Roggendorf et al. 2007).
In cases of copious bleeding from root canals, calcium hydroxide, anesthetic solution with 1:50,000 epinephrine or ferric sulfate placed on a sterile paper cone, are recognized as effective hemostatic agents (Magnusson 1971, Kouri et al. 1969, Dannenberg 1974).
The purpose of this study was to test the reduction of root canal bleeding in terms of significant percentage change for millimeters of blood in the canal at 2 different time points (baseline and after treatment with HybenX )
Detailed description
A new device (HYBENX®, EPIEN Medical, Saint Paul, MN, USA) has been developed with the purpose of destroying dental biofilm. The material is a mixture of hydroxybenzenesulfonic acid (37%) and hydroxymethoxybenzene acids (23%), sulfuric acid (28%), and water (12%).
This device has been successfully used in periodontology. Recent studies (Pini-Prato et al. 2016a, Isola et al. 2017) have demonstrated the effectiveness of the oral tissue decontaminant material in the treatment of clinical cases showing acute periodontal abscess without the use of systemic or local antibiotics. Similar favorable effects were obtained in the treatment of peri-implant mucositis and peri-implantitis (Pini-Prato et al. 2016b, Lopez et al. 2016). In addition, a randomized controlled trial (RCT) also demonstrated beneficial effects of the material in the treatment of oral aphthae (Porter et al. 2009).
Based on this scientific information, a clinical and microbiological study has been planned using the decontaminant device in cases of teeth with necrotic pulp with the aim to destroy the dental biofilm of root canals. The ability of the decontaminant device to immediately stop bleeding during canal instrumentation was found out accidentally during the procedures of this still unpublished trial.
Due to this fact, the authors were interested in evaluating the coagulation property of the material. The purpose of this study was to test the reduction of root canal bleeding in terms of significant percentage change for millimeters of blood in the canal at 2 different time points (before and after treatment with HybenX ) A single center, participants and data analyst blind, two-arm, randomized, placebo controlled clinical trial study was performed following the CONSORT statement in the Endodontics Department, University Hospital Florence Careggi, Florence, Italy.
The study population consisted of patients that were treated by Endodontics Department of the University Hospital of Florence Careggi, Italy. Subject inclusion criteria were: patients aged between 20 and 60 years, able and willing to sign a consent form, single-rooted teeth with necrotic pulp confirmed by electric vitality test, associated with healthy periodontium, physiologic sulcus depth (<3 mm), and absence of bleeding on probing of the involved teeth.
Exclusion criteria were: patients with systemic diseases using anticoagulants, antibiotics, or anti-inflammatory therapies in the last 30 days, patients with allergy to sulfur in any form, and pregnancy. All subjects were informed of the nature and potential risks and benefits of their participation in the study. They also received information on the duration of the procedure, and the possible intraoperative and postoperative complications.
Treatment The root canal therapy procedure was standardized and limited to one experienced endodontist (R.P.). Treatments were performed at the Endodontics Departments of the University Hospital of Florence Careggi, Italy, under local anesthesia using 1.8 mL mepivacaine hydrochloride (Optocaine; Molteni Dental SRL, Scandicci, Italy), and the teeth were isolated with rubber dams. After preparing the access cavity, the working length was determined with an electronic apex locator (Propex II Dentsply Maillefer Instruments, Ballaigues, Switzerland) with a size 10 k-file. Root canals were shaped using ProTaper Universal NiTi files (Dentsply Maillefer Instruments, Ballaigues, Switzerland) in the following sequence: S1, S2, F1, F2, F3 until each instrument reached the working length. After each instrument, the root canals were rinsed with NaClO (Niclor 5, Ogna, Italy) using a syringe with a side-vented 30 G needle. ProTaper NiTi instruments were driven with an endodontic motor (XSmart Endo Motor, Dentsply Maillefer Instruments, Ballaigues, Switzerland) with a 16:1 contrangle set up as suggested by the manufacturer.
After the root canal, shaping was performed, and a first sterile paper point was introduced in the root canal, up to the working length, for 10 seconds to detect blood presence.
With a caliber, on the sterile paper cone, the millimeters of blood present within the root canal were measured.
Only the teeth that at this point showed 1 or more millimeters of blood within the root canal were included in the present study and randomized to the two experimental groups.
Before further treatment, the teeth were allocated to an experimental (HybenX) or a control group (sterile saline solution) according to an uneven block randomization designed by the statistician (A.N.). For each tooth, a closed envelope was opened in a consecutive order, assigning the tooth to either the experimental or the control group HybenX was approved as a Class I CE medical device by the Italian Ministry of Health (no. 483768) on February 7, 2012.
HybenX Group The material was introduced inside the root canal using the pre-dosed syringe for 20 seconds with a sterile paper point with and up and down movement up to the working length.
Finally, the canal was rinsed with sterile water using a syringe with a side-vented 30 G needle 1 mm shorter than the working length.
A second sterile paper point was introduced in the root canal, up to the working length, for 10 seconds to detect the presence of blood and the millimeters of blood inside the root canal was measured again according the previous criteria.
Statistical Analysis Data were analyzed using SAS Version 9.3 software (SAS Institute, Inc., Cary, NC). A preliminary Levene's test was performed to verify the homogeneity of variance for the percentage change in the two groups.
Since the two groups showed homogeneity of the variance a t-test was performed to verify the null hypothesis by using a type I error equal to 0.05.
In order to confirm the firmness of the results a Wilcoxon non-parametric test was also carried out.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- single center, participants and data analyst blind, two-arm, randomized, placebo controlled clinical trial study
| Arm | Type | Receives |
|---|---|---|
| HybenX ® | Experimental | Device: HybenX1 cc of mixture of hydroxybenzenesulfonic acid (37%) and hydroxymethoxybenzene acids (23%), sulfuric acid (28%), and water (12%) for 20 sec |
| Control | Placebo comparator | Other: Placebo control5 cc of sterile saline water for 20 sec |
Who may qualify
- Ages
- 20 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- patients aged between 20 and 60 years
- patients able and willing to sign a consent form,
- single-rooted teeth with necrotic pulp confirmed by electric vitality test
- healthy periodontium
- physiologic sulcus depth (<3 mm)
Key exclusion criteria (7 listed)
- patients with systemic diseases
- patients using anticoagulants in the last 30 days
- patients using antibiotics in the last 30 days
- patients using anti-inflammatory therapies in the last 30 days
- patients with allergy to sulfur in any form
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| HybenXThe material was introduced inside the root canal using the pre-dosed syringe for 20 seconds with a sterile paper point with and up and down movement up to the working length. Finally, the canal was rinsed with sterile water using a syringe with a side-vented 30 G needle 1 mm shorter than the working length. A second sterile paper point was introduced in the root canal, up to the working length, for 10 seconds to detect the presence of blood and the millimeters of blood inside the root canal was measured again according the previous criteria. | Device | HybenX ® |
| Placebo controlThe root canal was irrigated with sterile saline water with a syringe and a side-vented 30G needle activated for 20 seconds with a sterile paper point with and up and down movement up to the working length to ensure a flow of irrigant solution throughout the canal. Finally, the canal was rinsed with sterile water using a syringe with a side-vented 30 G needle 1 mm shorter than the working length. A second sterile paper point was introduced in the root canal, up to the working length, for 10 seconds to detect the presence of blood and the millimeters of blood inside the root canal was measured again according the previous criteria. | Other | Control |
Primary outcome
Change From Baseline in Root Canal Bleeding
Time frame: Baseline and After Treatment (20 seconds)
After the root canal, shaping was performed a first sterile paper point was introduced in the root canal, up to the working length, to detect blood presence. The millimeters of blood on the paper point were measured with a caliber. After the intervention (HybenX or placebo) a second sterile paper point was introduced in the root canal, up to the working length, to detect the presence of blood according the previous criteria
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Mar 2019.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Background: PubMed 27100808Pini-Prato G, Magnani C, Rotundo R. Nonsurgical Treatment of Peri-implantitis Using the Biofilm Decontamination Approach: A Case Report Study. Int J Periodontics Restorative Dent. 2016 May-Jun;36(3):383-91. doi: 10.11607/prd.2653.
- Background: PubMed 28042438Lopez MA, Andreasi Bassi M, Confalone L, Silvestre F, Arcuri C. The treatment of peri-implant diseases: a new approach using hybenx(R) as a decontaminant for implant surface and oral tissues. Oral Implantol (Rome). 2016 Nov 13;9(3):106-114. doi: 10.11138/orl/2016.9.3.106. eCollection 2016 Jul-Sep.
- Background: PubMed 19207485Porter SR, Al-Johani K, Fedele S, Moles DR. Randomised controlled trial of the efficacy of HybenX in the symptomatic treatment of recurrent aphthous stomatitis. Oral Dis. 2009 Mar;15(2):155-61. doi: 10.1111/j.1601-0825.2008.01503.x.
- Background: PubMed 18155498Zmener O, Pameijer CH, Serrano SA, Vidueira M, Macchi RL. Significance of moist root canal dentin with the use of methacrylate-based endodontic sealers: an in vitro coronal dye leakage study. J Endod. 2008 Jan;34(1):76-9. doi: 10.1016/j.joen.2007.10.012.
- Background: PubMed 17185125Roggendorf MJ, Ebert J, Petschelt A, Frankenberger R. Influence of moisture on the apical seal of root canal fillings with five different types of sealer. J Endod. 2007 Jan;33(1):31-3. doi: 10.1016/j.joen.2006.07.006. Epub 2006 Oct 13.
- Background: PubMed 5280515Magnusson B. Therapeutic pulpotomy in primary molars--clinical and histological follow-up. II. Zinc oxide-eugenol as wound dressing. Odontol Revy. 1971;22(1):45-54. No abstract available.
- Background: PubMed 4888301Kouri EM, Matthews JL, Taylor PP. Epinephrine in pulpotomy. ASDC J Dent Child. 1969 Mar-Apr;36(2):123-8. No abstract available.
- Background: PubMed 4274315Dannenberg JL. Pedodontic endodontics. Dent Clin North Am. 1974 Apr;18(2):367-77. No abstract available.
- Background: PubMed 28624914Isola G, Matarese G, Williams RC, Siciliano VI, Alibrandi A, Cordasco G, Ramaglia L. The effects of a desiccant agent in the treatment of chronic periodontitis: a randomized, controlled clinical trial. Clin Oral Investig. 2018 Mar;22(2):791-800. doi: 10.1007/s00784-017-2154-7. Epub 2017 Jun 17.
- Background: PubMed 26697553Pini-Prato G, Magnani C, Rotundo R. Treatment of Acute Periodontal Abscesses Using the Biofilm Decontamination Approach: A Case Report Study. Int J Periodontics Restorative Dent. 2016 Jan-Feb;36(1):55-63. doi: 10.11607/prd.2557.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing HybenX in people with Blood Contamination of Root Canal During Endodontic Therapy, run by Dr Riccardo Pace at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Mar 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 13 Mar 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline in Root Canal Bleeding (time frame: Baseline and After Treatment (20 seconds)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03336853, which also lists 10 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Mar 2019.